DelveInsight’s, “Chronic Obstructive Pulmonary Disease Pipeline Insight 2023” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including Chronic Obstructive Pulmonary Disease clinical trials and nonclinical stage products. It also covers the Chronic Obstructive Pulmonary Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Treatment Landscape

 

• In April, 2023, Nuance Pharma announced that the first COPD patient had received a dose in the ENHANCE – CHINA Phase III trial (RPL554 – CPC001; NCT05743075). This trial is a randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of Ensifentrine over a 24-week period in patients with moderate to severe COPD.

 

• In March, 2023, Nuance Pharma completed the first dose of the first healthy subject in the Phase I trial (RPL554 – AHC001; NCT05758428), a PK, safety, and tolerability investigation of nebulized Ensifentrine on healthy Chinese volunteers.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Obstructive Pulmonary Disease Pipeline landscape @ Chronic Obstructive Pulmonary Disease Pipeline Outlook

 

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases.

 

Key Takeaways from Chronic Obstructive Pulmonary Disease Pipeline Report

 

• DelveInsight’s Chronic Obstructive Pulmonary Disease Pipeline report depicts a robust space with 65+ active players working to develop 70+ pipeline therapies for Chronic Obstructive Pulmonary Disease treatment.

 

• The leading Chronic Obstructive Pulmonary Disease Companies include Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others

 

• Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies include Benralizumab, Tezepelumab, SNG001, Zofin, GSK3923868, GRC 39815, UMC 119 06, and others

 

• The Chronic Obstructive Pulmonary Disease companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The Chronic Obstructive Pulmonary Disease therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

 

For further information, refer to the detailed Chronic Obstructive Pulmonary Disease Drugs Launch, Chronic Obstructive Pulmonary Disease Developmental Activities, and Chronic Obstructive Pulmonary Disease News, click here for Chronic Obstructive Pulmonary Disease Ongoing Clinical Trial Analysis

 

Chronic Obstructive Pulmonary Disease Emerging Drugs Profile

 

• Benralizumab: AstraZeneca

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG, which gives it a high affinity for the FcγRIIIα receptor in natural killer cells, macrophages, and neutrophils. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation, and migration to the lungs. The drug is currently in Phase III stage of its clinical trial evaluation to treat COPD.

 

• Dupilumab: Sanofi

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.

 

• Tezepelumab: Amgen

Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.

 

• SNG001: Synairgen

SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.

               

• GSK3923868: GlaxoSmithKline

GSK3923868, is a PI4kβ inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.

 

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment

There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

Find out more about the Chronic Obstructive Pulmonary Disease Pipeline Segmentation, Therapeutics Assessment, and Chronic Obstructive Pulmonary Disease Emerging Drugs @ Chronic Obstructive Pulmonary Disease Treatment Landscape

 

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report

 

• Coverage- Global

 

• Chronic Obstructive Pulmonary Disease Companies- Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others

 

• Chronic Obstructive Pulmonary Disease Pipeline Therapies- Benralizumab, Tezepelumab, SNG001, Zofin, GSK3923868, GRC 39815, UMC 119 06, and others

 

• Chronic Obstructive Pulmonary Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Obstructive Pulmonary Disease Pipeline Companies and Therapies, click here @ Chronic Obstructive Pulmonary Disease Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Obstructive Pulmonary Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tezepelumab: Amgen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GSK3923868: GlaxoSmithKline
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Obstructive Pulmonary Disease- Unmet Needs
21. Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
22. Appendix

 

Got Queries? Find out the related information on Chronic Obstructive Pulmonary Disease Mergers and acquisitions, Chronic Obstructive Pulmonary Disease Licensing Activities @ Chronic Obstructive Pulmonary Disease Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/